Safinamide
| Clinical data | |
|---|---|
| Trade names | Xadago, others |
| Other names | EMD-1195686, PNU-15774E; (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl] methylamino]propanamide |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Reversible monoamine oxidase B inhibitor, Serotonin-dopamine reuptake inhibitor, Antiparkinsonian |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 88–90% |
| Metabolism | Amidases, glucuronidation |
| Elimination half-life | 20–30 hrs |
| Excretion | 76% Kidney, 1.5% faeces |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.120.167 |
| Chemical and physical data | |
| Formula | C17H19FN2O2 |
| Molar mass | 302.349 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Safinamide, sold under the brand name Xadago among others, is a medication used as treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.
It was approved in the European Union in February 2015, in the United States in March 2017, and in Canada in January 2019.